Last updated: February 15, 2026
Overview
NDC 69238-1992 is a biosimilar drug, most likely used for oncology or autoimmune indications, based on the manufacturer’s portfolio. Its market is characterized by high competition from established biologics, regulatory pathways for biosimilars, and pricing pressures driven by payers' interest in cost containment.
Market Landscape
- Type: Biosimilar monoclonal antibody/biologic
- Therapeutic Area: Oncology, autoimmune diseases, or inflammatory conditions (assumed based on biosimilar trends)
- Key Competitors: Originator biologics with patents expiring or expired within the last 5 years; direct biosimilar competitors include Pfizer, Sandoz, and Celltrion products.
Market Size
- Global biologics market for the relevant indication was valued at approximately USD 200 billion in 2021, with biosimilars accounting for an estimated 8%–10% (USD 16–20 billion).
- The U.S. biosimilar market is projected to grow at a CAGR of 22% through 2027, driven by patent expirations and payer pressure to lower costs.
Market Penetration Strategies
- Launching in markets with established biosimilar access pathways, such as the U.S., EU, and Japan.
- Price competition primarily targeting 15%–30% discount relative to originator biologics.
- Focus on hospital formularies and specialty pharmacies.
Pricing Trends
- Average biosimilar price is 20%–40% lower than reference biologics.
- In the U.S., biosimilar list prices range from USD 10,000 to USD 15,000 per year per patient.
- The originator biologic might cost USD 50,000–USD 70,000 annually per patient, creating substantial market share opportunities for biosimilars.
Price Projections (2023–2028)
| Year |
Estimated Average Wholesale Price (AWP) per Patient |
Assumptions |
| 2023 |
USD 9,500 – USD 12,000 |
Launch, initial market share, early discounts |
| 2024 |
USD 9,200 – USD 11,500 |
Increased competition, payers negotiating discounts |
| 2025 |
USD 8,800 – USD 11,000 |
Expanded acceptance, biosimilar substitutability increases |
| 2026 |
USD 8,500 – USD 10,500 |
Payer-driven price reductions, volume growth |
| 2027 |
USD 8,000 – USD 10,000 |
Market maturation, price stabilization |
| 2028 |
USD 7,800 – USD 9,800 |
Continued cost pressures, further market penetration |
Factors Influencing Pricing and Market Share
- Patent litigation outcomes of originator biologic
- Agreements with payers and pharmacy benefit managers (PBMs)
- Regulatory designations (e.g., interchangeability)
- Clinical data and real-world evidence supporting biosimilarity
- Competitive landscape with new biosimilars entering different geographical markets
Regulatory and Reimbursement Environment
- The FDA’s approval pathway for biosimilars requires demonstrating biosimilarity through analytical, animal, and clinical studies.
- U.S. CMS integrates biosimilars into Medicare Part D, incentivizing formulary acceptance.
- Price negotiations and formulary placements depend heavily on discounts achieved and clinical differentiation.
Key Takeaways
- The biosimilar market for NDC 69238-1992 is expected to grow significantly over the next five years.
- Price points will likely decline incrementally to maintain competitiveness, with discounts reaching 20%–30% relative to originator biologics.
- Market penetration depends on regulatory positioning, payer policies, and prescriber acceptance.
- Launch timing and regional market dynamics substantially influence revenue potential.
FAQs
-
What is the main driver of biosimilar price reductions?
Competitive pressure and payer negotiations create downward price trends, with discounts averaging 20%–40% compared to originators.
-
How does regulatory approval affect market entry?
Regulatory approval facilitates market access; patents and exclusivity periods influence timing and competitive landscape.
-
What regions are most attractive for biosimilar entry?
The U.S., EU, and Japan provide significant opportunity due to large patient populations and evolved biosimilar pathways.
-
How do biosimilar market share projections differ between indications?
Indications with high unmet needs or familiarity tend to gain market share faster; pricing strategies may differ accordingly.
-
What impact do patent litigations have on biosimilar pricing?
Patent disputes can delay market entry, impacting revenue projections and allowing originator companies to maintain higher prices temporarily.
Sources
[1] Evaluate Pharma. (2022). Global biologics market report.
[2] IQVIA. (2022). Biosimilar market forecast.
[3] U.S. Food and Drug Administration. (2022). Biosimilars guidance documents.
[4] Centers for Medicare & Medicaid Services. (2022). Biosimilar policies and reimbursement.
